Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | YL-13027 |
Synonyms | |
Therapy Description |
YL-13027 inhibits type 1 TGF-beta receptor, which may modulate tumor microenvironment, potentially leading to inhibition of tumor growth (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 3098-3098). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
YL-13027 | YL 13027|YL13027 | TGFBR1 inhibitor 16 | YL-13027 inhibits type 1 TGF-beta receptor, which may modulate tumor microenvironment, potentially leading to inhibition of tumor growth (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 3098-3098). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05228600 | Phase I | YL-13027 | YL-13027 in Patients With Advanced Solid Tumors | Unknown status | USA | 0 |